CASI Pharmaceuticals (CASI) Competitors

Opthea (NASDAQ:OPT) and CASI Pharmaceuticals (NASDAQ:CASI) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, earnings, valuation, media sentiment, risk, analyst recommendations, profitability, institutional ownership and community ranking.

Do analysts prefer OPT or CASI?

Opthea currently has a consensus target price of $12.00, suggesting a potential upside of 230.58%. CASI Pharmaceuticals has a consensus target price of $6.00, suggesting a potential upside of 112.77%. Given Opthea's stronger consensus rating and higher possible upside, research analysts plainly believe Opthea is more favorable than CASI Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Opthea	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.50
CASI Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has more risk and volatility, OPT or CASI?

Opthea has a beta of 1.07, meaning that its stock price is 7% more volatile than the S&P 500. Comparatively, CASI Pharmaceuticals has a beta of 0.56, meaning that its stock price is 44% less volatile than the S&P 500.

Does the media prefer OPT or CASI?

In the previous week, Opthea had 7 more articles in the media than CASI Pharmaceuticals. MarketBeat recorded 7 mentions for Opthea and 0 mentions for CASI Pharmaceuticals. CASI Pharmaceuticals' average media sentiment score of 0.00 beat Opthea's score of -0.12 indicating that CASI Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Opthea	Neutral
CASI Pharmaceuticals	Neutral

Does the MarketBeat Community believe in OPT or CASI?

CASI Pharmaceuticals received 183 more outperform votes than Opthea when rated by MarketBeat users. However, 53.13% of users gave Opthea an outperform vote while only 50.25% of users gave CASI Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
Opthea	Outperform Votes 17 53.13%	Underperform Votes 15 46.88%
CASI Pharmaceuticals	Outperform Votes 200 50.25%	Underperform Votes 198 49.75%

Do institutionals and insiders believe in OPT or CASI?

56.0% of Opthea shares are owned by institutional investors. Comparatively, 22.2% of CASI Pharmaceuticals shares are owned by institutional investors. 3.2% of Opthea shares are owned by insiders. Comparatively, 21.2% of CASI Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Which has higher earnings and valuation, OPT or CASI?

CASI Pharmaceuticals has higher revenue and earnings than Opthea.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Opthea	$124.67K	1,700.33	-$220.24M	N/A	N/A
CASI Pharmaceuticals	$22.06M	1.98	-$26.94M	-$2.23	-1.26

Is OPT or CASI more profitable?

Opthea has a net margin of 0.00% compared to CASI Pharmaceuticals' net margin of -143.18%. Opthea's return on equity of 0.00% beat CASI Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Opthea	N/A	N/A	N/A
CASI Pharmaceuticals	-143.18%	-181.52%	-45.72%

Summary

Opthea beats CASI Pharmaceuticals on 11 of the 16 factors compared between the two stocks.